Edition:
United States

Profile: MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

4.97EUR
26 May 2017
Change (% chg)

€-0.01 (-0.20%)
Prev Close
€4.98
Open
€4.97
Day's High
€4.99
Day's Low
€4.95
Volume
30,635
Avg. Vol
220,631
52-wk High
€5.78
52-wk Low
€2.87

MDxHealth SA is a Belgium-based multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Company Address

MDxHealth SA

CAP Business Center, Rue d'Abhoo
HERSTAL     4040
P: +324.3642070
F: +324.3642071

Company Web Links